Clin2
NCT05577585Possibly a fitRecruiting

Ketamine treatment for obsessive-compulsive disorder symptoms

Obsessive-Compulsive DisorderPsychiatric Disorder

Treatments studied

Part of Mental health clinical trials.

This study tests whether ketamine can reduce obsessive-compulsive disorder (OCD) symptoms and how it affects stress and thinking. It also compares ketamine to usual care to see if benefits and side effects differ.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have a primary diagnosis of obsessive-compulsive disorder (OCD)
  • Your OCD symptom severity score is 16 or higher on the Yale-Brown OCD scale
  • You can give informed consent in writing
  • You have tried at least one other OCD treatment in the past
  • You can follow all study rules and attend required visits

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06575075Recruiting· Phase 1/Phase 2
Ketamine study for OCD

This study tests a form of ketamine called RR-HNK as a possible new treatment for OCD. It is for people who have not gotten enough relief from standard treatments or chose not to take them.

Palo Alto, California
NCT05940324Recruiting· Phase 2
Ketamine study for OCD after prior treatment failed

This Phase 2 study tests how ketamine may work quickly in people with obsessive-compulsive disorder (OCD), especially after at least one standard treatment didn’t help. If you join, you’ll need to follow study procedures like fasting before the experimental visit and not enrolling in other medication trials during the study.

Stanford, California
NCT05565352Enrolling by invitation
Ketamine safety study for people in inpatient psychiatric care

This trial looks at whether ketamine is safe and well-tolerated for certain mental health conditions when given in a hospital setting. It may help teams better understand side effects and comfort for people who may be offered ketamine.

Gdansk
NCT07139106Not yet recruiting· Phase 4
Ketamine and brain opioid receptors for suicidal thoughts

This study tests how ketamine affects brain chemicals linked to suicidal thoughts in people with depression. You will receive ketamine and have brain scans (PET and MRI) to see if it changes activity in opioid receptors.

New York, New York
NCT06668571Recruiting· Phase 2
Ketamine for treatment-resistant depression

This study tests if intravenous ketamine can help people with treatment-resistant depression who haven't found relief from at least two other treatments. If you qualify, you'll receive ketamine infusions to see if it improves your mood.

Rochester, Minnesota
NCT06788249Recruiting· Early Phase 1
Ketamine for treatment-resistant depression brain study

This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.

Philadelphia, Pennsylvania

Hear when a new Obsessive-Compulsive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.